Why We're Excited About the New HIV Drug, Tivicay

GlaxoSmithKline's long-awaited integrase inhibitor-class drug, Ticivay (dolutegravir), received approval on Monday from the U.S. Food and Drug Administration. The once-daily HIV treatment is the third drug of its class to receive FDA approval, following in the footsteps of Isentress (raltegravir) in 2007 and elvitegravir (a component of the "quad pill," Stribild) in 2012....Read Full Post
Source: About AIDS / HIV - Category: Consumer Health News Source Type: news